Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel - CEO Interview

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's largest drug maker Ranbaxy is confident that the U.S. Department of Justice will soon withdraw its motion filed against the company, Ranbaxy CEO Malvinder Singh said in an interview with PharmAsia News
Advertisement

Related Content

Let The Blame Game Begin: Former Ranbaxy Promoter Spars With Daiichi Sankyo
Ranbaxy CEO Malvinder Singh On U.S. FDA’s Investigation And The Daiichi Sankyo Deal: An Interview With PharmAsia News
Ranbaxy CEO Malvinder Singh On U.S. FDA’s Investigation And The Daiichi Sankyo Deal: An Interview With PharmAsia News
Ranbaxy Granted 60 Days To Produce Audit Documents in DOJ Investigation
Ranbaxy Granted 60 Days To Produce Audit Documents in DOJ Investigation
Ranbaxy Alleges Rivals Of Meddling With Daiichi Sankyo Deal; U.S. House Committee Enters Fray
Analysts Endorse Ranbaxy-Pfizer Deal On Lipitor
Ranbaxy Will Produce Internal Audits To U.S. DOJ But Warns Of Impact To Industry From "Bad Policy"
Ranbaxy Will Produce Internal Audits To U.S. DOJ But Warns Of Impact To Industry From "Bad Policy"
Indian Drug Majors Settle Generic Lawsuits
Advertisement
UsernamePublicRestriction

Register

SC069142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel